To find an effective chemotherapy agent for treating PDAC with KRAS-G12D mutations, a library of GPCR-targeted drug molecules was tested in human PDAC cell lines, mouse pancreatic cancer-associated stellate cell lines, and 60 different human tumor cell lines (Song et al., 2018). The gene discussed is KRAS; the disease is neoplasm.